BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Rosiglitazone
,
rs2230926
,
IGF1
,
nitric oxide metabolic process
,
Ischemia
,
Breast
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CUDC-101
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib…
Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting …
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-1…
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients Wit…
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous C…
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Pati…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ